Home  |   Companies  |   Targets  |   Drugs  |   Diseases  |   Search  |   Help  |   About Blog Blog | Twitter Twitter | Rss SciBite News | Contact Contact   
LogoBeta Software
Open Drug Discovery Intelligence
     
searchSearch Scibite.com

Targets, Diseases & Drug Names All News
a- A+
SCIBITE NEWS:

Effect of transcatheter renal arterial embolization combined with cryoablation on regulatory CD4 + CD25 + T lymphocytes in the peripheral blood of patients with advanced renal carcinoma
Tue Apr 24 15:02:30 BST 2012
Key Topics

Click on any of the topic names to view its own newsletter. The text we matched to the topic is shown in grey underneath.

 ISG20, interferon stimulated exonuc..

[matched:cd25]

 IL2RA, interleukin 2 receptor, alpha

[matched:cd25]

 Renal Cell Carcinoma

[matched:renal carcinoma, renal cell carcinoma]

 Kidney Neoplasms

[matched:renal carcinoma, renal cell carcinoma]

Altmetric Article Ranking
Altmetric is a new way of monitoring impact of journal articles across social media, provided by altmetric.com. Click on the badge to see more information about this article from Altmetric.

   
To analyze the effect of Argon-Helium cryosurgery (AHCS) combined with transcatheter renal arterial embolization (TRAE) on the differentiation of regulatory CD4(+) CD25(+) T cell (Treg) and its implication in patients with renal carcinoma. METHODS: Seventy seven patients are included in the study, and divided into two groups: TRAE group (n=45, receiving TRAE only) and TRAE+cryoablation group (n=32, receiving cryoablation 2-3weeks after TRAE). The percentage of Treg cells and T lymphocyte subsets (CD4(+)T, CD8(+)T, and CD4(+)T/CD8(+)T) in the peripheral blood is measured by flow cytometry previous to the therapy and 3months after therapy. Meanwhile, the extent of tumor necrosis is measured by MRI or CT 1month after therapy. RESULTS: The percentages of Treg cells of patients in TRAE+cryoablation group decrease from (6.65+/-1.22)% to (3.93+/-1.16)%, (t=42.768, P<0.01), and the percentages of CD4(+)T and CD4(+)T/CD8(+)T increase significantly (P<0.01). However, the results of patients in TRAE group show that the percentages of Treg, CD4(+)T, CD8(+)T and CD4(+)T/CD8(+)T increase slightly although the differences had no statistical significance (P>0.05). The tumor necrosis rate of TRAE+cryoablation group is 57.5%, significantly higher than those of TRAE group, which shows 31.6% (t=6.784, P<0.01). The median survival duration of the TRAE+cryoablation group is 20months, significantly longer than that of the TRAE group (chi(2)=7.368, P<0.01). The decreasing extent of Treg cells is correlated with tumor necrosis rates (r=0.90, P<0.01) and life time (r=0.67, P<0.01). CONCLUSION: The therapy of TRAE combined with cryoablation contributes to reduce the percentage of Treg cells and improve the immune situation of patients with renal cell carcinoma, which consequently increase tumor necrosis rate and prolong the patients' survival duration;   Read more on this story here

Source: ncbi.nlm.nih.gov   (view original)
Inst: Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
   abstracted provided by MEDLINE/PubMed, a database of the U.S. National Library of Medicine.

Summary Loaded